| A Randomized Study in Non-Hodgkin's Lymphoma Patients Carrying Hepatitis B Surface Antigen (NCT00201318) | National Health Research Institutes, Taiwan | 2001-09-01 |
| Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL (NCT01851551) | Acrotech Biopharma Inc. | 2001-09-01 |
| The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen (NCT01890486) | Wake Forest University Health Sciences | 2001-05-21 |
| A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma (NCT00038545) | M.D. Anderson Cancer Center | 2001-05-18 |
| CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation (NCT00038818) | M.D. Anderson Cancer Center | 2001-05-01 |
| Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor (NCT00582933) | Memorial Sloan Kettering Cancer Center | 2001-05-01 |
| Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies (NCT00013533) | National Cancer Institute (NCI) | 2001-03-14 |
| Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma (NCT00163748) | Bayside Health | 2001-02-01 |
| Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG (NCT00061425) | Gilead Sciences | 2000-08-01 |
| Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer (NCT00588263) | Memorial Sloan Kettering Cancer Center | 2000-07-01 |
| Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL) (NCT00051025) | Eisai Inc. | 2000-05-01 |
| The Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment Planning (NCT00588328) | Memorial Sloan Kettering Cancer Center | 2000-03-01 |
| Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy (NCT00183950) | University of Southern California | 2000-03-01 |
| Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP (NCT00022932) | Corixa Corporation | 2000-01-01 |
| Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants (NCT00001830) | National Cancer Institute (NCI) | 1999-07-20 |
| Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement (NCT00022906) | Corixa Corporation | 1999-05-01 |
| Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809) (NCT00133302) | Japan Clinical Oncology Group | 1999-02-01 |
| A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma (NCT01388959) | Hoffmann-La Roche | 1998-11-01 |
| A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma (NCT00269113) | Hoffmann-La Roche | 1998-09-01 |
| Expanded Access Study of Iodine-131 Anti-B1 Antibody (NCT00022958) | Corixa Corporation | 1998-09-01 |
| Interdisciplinary Case-Control Study of Non-Hodgkin's Lymphoma (NCT00341952) | National Cancer Institute (NCI) | 1998-04-15 |
| Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma (NCT00225212) | Stanford University | 1997-11-01 |
| A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma (NCT01392716) | Hoffmann-La Roche | 1997-10-01 |
| AIDS and Cancer Specimen Bank (ACSB) (NCT00587912) | Memorial Sloan Kettering Cancer Center | 1997-06-01 |
| Spectroscopy With Surface Coils and Decoupling (NCT00581815) | Memorial Sloan Kettering Cancer Center | 1997-02-01 |
| A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma (NCT01998893) | Hoffmann-La Roche | 1997-01-01 |
| High Dose CHOP in Lymphoma (NCT00192764) | Rambam Health Care Campus | 1996-12-01 |
| Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States (NCT00038779) | M.D. Anderson Cancer Center | 1996-08-14 |
| A Comparative Study for Non-Hodgkin's Lymphoma in Hepatitis B Virus Carriers (NCT00262210) | National Health Research Institutes, Taiwan | 1995-06-01 |
| A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas (NCT00001430) | National Cancer Institute (NCI) | 1995-02-01 |
| A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma (NCT00117455) | Amgen | |
| Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade) (NCT00044902) | Amgen | |
| Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib (NCT04757259) | Alexion Pharmaceuticals, Inc. | |
| This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant. (NCT00720603) | Genzyme, a Sanofi Company | |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma (NCT00022893) | Corixa Corporation | |
| Expanded Access to Venetoclax (NCT03123029) | AbbVie | |